CONSENT AGENDA

BOARD MEETING 6-7 June 2018, Geneva



Recommendation 1: Consent Agenda: Vice Chair Appointment

The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board that it:

- a) Reappoint William (Bill) Roedy as an Unaffiliated Board member through to 31 July 2021; and
- **Appoint** William (Bill) Roedy as Vice Chair of the Board with individual signatory authority effective 1 July 2018 through 31 December 2019.



Recommendation 2: Consent Agenda: Board/Committee Member Appointments

The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board that it:

- a) **Appoint** the following Board Member:
 - Amir Aman Hagos of Ethiopia as Board Member representing the developing country constituency in the seat currently held by Yifru Berhan Mitke of Ethiopia effective immediately and until 31 December 2020.
- **b)** Appoint the following to the Governance Committee effective immediately:
 - Amir Aman Hagos (Board Member) until 31 December 2019.



Recommendation 3: Consent Agenda: Independent Review Committee Appointments

The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board that it:

Appoint as new IRC members the individuals listed in Annex A to Doc 07a for terms effective immediately until 31 March 2021.



Recommendation 4: Consent Agenda: Independent Auditor Appointment

The Gavi Alliance Audit and Finance Committee recommends to the Gavi Alliance Board that it:

- a) Appoint Deloitte SA as the Independent Auditor of Gavi for the 5-year term from 2018 to 2022.
- **b)** Appoint Deloitte SA as the external tax consultant of Gavi for the 5-year term from 2018 to 2022.



Recommendation 5: Consent Agenda: Governance Committee Charter

The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board that it:

Approve the revised and updated Governance Committee Charter as set out in Annex A to Doc 06, effective from 1 July 2018.



Recommendation 6: Consent Agenda: Independent Review Committee Terms of Reference

The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board that it:

Approve the amended Terms of Reference of the Independent Review Committee attached as Annex A to Doc 07b.



Recommendation 7: Consent Agenda: Review of Conflicts of Interest Policy

The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board that it:

- a) <u>Approve</u> the draft Conflicts of Interest Policy for Governance Bodies set out in Annex A to Doc 02g, effective from 1 January 2019; and
- **b)** Amend Article 28 of the Statutes to read as follows:

"To preserve transparency in financial arrangements, the Board shall adopt a conflicts of interest policy for all organs of the Gavi Alliance, with the exception of the Secretariat conflicts of interest policy which will be approved by the Governance Committee."



Recommendation 8: Consent Agenda: Changes in 2016-2020 Strategic Indicators

- **Approve** the changes to the definitions and targets of the Strategy Indicators as set out in Annex A to Doc 02h; and
- **b)** Request the Secretariat to also continue tracking the original definitions and targets of these Strategic Indicators for monitoring purposes.



Recommendation 9: Consent Agenda: Reflecting Board-Approved Changes to Eligibility and Transition Policy

The Gavi Alliance Programme and Policy Committee recommends to the Gavi Alliance Board that it:

Approve the following modifications to Gavi's Eligibility and Transition Policy:

- 7.6 Countries are eligible to apply for new vaccine support during the five years of Phase 2, provided that vaccine introductions during this phase effectively contribute to strengthening routine immunisation and increasing coverage and equity.
- 7.6. 7.7 Countries that surpass the Eligibility Threshold have one year to apply for new HSS (i.e. for a country that has not received any HSS support from Gavi yet) and vaccine support, from January 1 of the year after surpassing the Eligibility Threshold (a grace year). However, new HSS support is restricted to those countries with Penta3 coverage below 90%.
- 7.7. From the second year in Phase 2, countries cannot submit new applications or resubmit previously rejected applications for any of Gavi's funding windows.



Recommendation 10: Consent Agenda: Modifications to Gavi's HSIS Support Framework and Gavi's Fragility, Emergency, Refugees Policy (1/3)

- **Reaffirm** its decision from June 2016, "that an amount of at least US\$ 1.3 billion is available for HSS disbursements (including performance payments) for grant programme years in the 2016-2020 strategic period, with additional funding being subject to future Board decisions";
- **Approve** the following wording to be included as an annex to Gavi's HSIS Support Framework (the "**Annex**"), noting that any increases to allocation ceilings for HSS support under the Annex will be subject to existing Board-approved review and approval processes:



Recommendation 10: Consent Agenda: Modifications to Gavi's HSIS Support Framework and Gavi's Fragility, Emergency, Refugees Policy (2/3)

"Annex – for Strategic Period 2016-2020

Notwithstanding Section VII (Funding levels and use of grants) of this Framework, the flexibility set out in this annex will apply as follows.

In order to advance Gavi's strategic goal of increasing immunisation coverage and equity, for the remainder of the strategic period through 2020, Gavi has the flexibility to increase an individual country's allocation ceiling for HSS support by up to 25% beyond the total amount of the ceiling calculated based on the HSS Resource Allocation Formula (in section VII Funding levels and use of grants). This flexibility applies to all countries except:

- Countries that have a separate Board-defined HSS ceiling,
- 2. Countries that are eligible for increased HSS support of up to 50% as per the amended Fragility, Emergencies, Refugees Policy.

This flexibility would be implemented country-by-country based on a careful assessment of both needs and absorptive capacity."



Recommendation 10: Consent Agenda: Modifications to Gavi's HSIS Support Framework and Gavi's Fragility, Emergency, Refugees Policy (3/3)

- c) <u>Note</u> that increases to allocation ceilings for HSS support under the Annex will not in aggregate exceed US\$ 1.5 billion for the 2016-2020 strategic period and that HSS disbursements will not exceed US\$ 1.3 billion in accordance with the June 2016 Board decision; and
- **Approve** the following addition to Section 5.7 of Gavi's Fragility, Emergencies, Refugees Policy as a potential flexibility for countries facing fragility challenges:
 - "e) Additional HSS support of up to 50% beyond the country allocation"



Recommendation 11: Consent Agenda: Extension of Support for Use of Gavi's Global Cholera Stockpile in Endemic Settings for 2019

- a) <u>Approve</u> an extension of Gavi support for use of the global cholera stockpile in endemic settings through 2019;
- **b)** <u>Authorise</u> the Secretariat, under the Programme Funding Policy, to (i) allot funding to the global cholera stockpile based on a financial forecast endorsed by the Board, (ii) allot funding to extend budgets to future years and/or (iii) adjust annual budget amounts as authorised by the CEO/DCEO taking into account updated timing of implementation and budget utilisation; and
- **Note** that the additional funding associated with the above approval is expected to be approximately US\$ 52 million to meet the 2019 needs.



Recommendation 12: Consent Agenda: Expansion of PCV Support to include catch-up during new introductions (1/2)

- a) <u>Approve</u> that Gavi supported countries introducing routine PCV are eligible to receive support for the vaccination of children between 1 and 5 years of age within the year following introduction as follows:
 - (i) For these additional cohorts, Gavi would provide 100% of vaccine support and cash support of up to US\$ 0.65 per targeted child (depending on the transition phase in accordance with the HSIS Support Framework);
 - (ii) This support will be subject to countries demonstrating how they will use the cash support for long-term strengthening of vaccine delivery through the routine immunisation programme;



Recommendation 12: Consent Agenda: Expansion of PCV Support to include catch-up during new introductions (2/2)

- (iii) For countries planning to run campaigns for other vaccines in the same year, the level of support will take into account budget efficiencies and implementation synergies; and
- **b)** Note that additional funding associated with the above approval is expected to be up to approximately US\$ 18.7 million for the 2018-2020 period.



Recommendation 13: Consent Agenda: Mid-term approach to replace reactive approvals of continuation of support in South Sudan

- a) <u>Approve</u> that South Sudan is exempted from its obligations to co-finance from 2017 to 2020 given its exceptional context and socio-political and economic prospects; and
- **b)** Note that the additional funding associated with the above approval is expected to be up to approximately US\$ 650,000.



Thank you



